Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21770795 | 0.98 | KCNH2 (0.38) | KCNH2GPR84CHRM2CHRM5CHRM1 | |
| SCHEMBL7082422 | 0.94 | — | — | |
| SCHEMBL989895 | 0.87 | CES1 (0.38) | L3MBTL1CES1 | |
| SCHEMBL18462195 | 0.77 | HTR1A (0.38) | KCNH2CHRM2CHRM1ADRA2ASLC6A2 | |
| SCHEMBL2095540 | 0.72 | CHRM2 (0.37) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL20969048 | 0.71 | TLR7 (0.33) | TLR7ALDH1A1 | |
| SCHEMBL18462051 | 0.71 | CES1 (0.51) | TDP1L3MBTL1SLC6A3ALDH1A1HTR2C | |
| SCHEMBL15407620 | 0.69 | PSEN1 (0.31) | L3MBTL1 | |
| SCHEMBL87389 | 0.69 | NAAA (0.47) | KCNH2GPR84PTGS2CYP3A4TDP1 | |
| SCHEMBL15225261 | 0.67 | NAAA (0.50) | KCNH2GPR84CYP3A4TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | claimed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| EP-4192821-A1 | ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2023-06-14 | — | — | EP | disclosed |
| EP-4186899-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-110372626-B | Method for preparing 1,2, 4-oxadiazole compound | 河南大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-104892591-A | Preparation method of pyrazole oxime compound containing 3-aryl-1,2,4-oxdiazole heterocycle structure and application thereof | UNIV NANTONG | 2015-09-09 | — | — | CN | disclosed |
| CN-104892591-A | Preparation method of pyrazole oxime compound containing 3-aryl-1,2,4-oxdiazole heterocycle structure and application thereof | UNIV NANTONG | 2015-09-09 | — | — | CN | disclosed |
| EP-2903984-A1 | BICYCLIC 1, 2, 4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8957051-B2 | Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140100197-A1 | BICYCLIC 1, 2, 4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014055916-A1 | SUBSTITUTED ARYL-1,2,4-OXADIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF INTERALIA OCULAR OR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| EP-2155718-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148710-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-0061882-A1 | Process for preparing isoxazol-3-ylcarboxamides | ELI LILLY AND COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | KCNH2 2861/4885GPR84 258/4885CHRM2 1777/4885 |
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | KCNH2 3189/4885GPR84 76/4885CHRM2 1730/4885 |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | KCNH2 3189/4885GPR84 76/4885CHRM2 1730/4885 |
| US-20140100197-A1 | BICYCLIC 1, 2, 4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR2 | KCNH2 2978/4885GPR84 76/4885CHRM2 1406/4885 |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | SSTR5, NPY5R, SSTR3 | KCNH2 2416/4885GPR84 63/4885CHRM2 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.